Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  navitoclax
Find trials that include:  Any drugs shown
Results 1-5 of 5 for your search:
Start Over
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-505, NCI-2014-00461, 9525, NCT02079740
Dabrafenib, Trametinib, and Navitoclax in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-424, NCI-2013-02103, NCT01970956, 9466, NCT01989585
Navitoclax and Abiraterone Acetate with or without Hydroxychloroquine in Treating Patients with Progressive Metastatic Castrate Refractory Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18 to 90
Trial IDs: 081214, NCI-2013-02403, NCT01828476
Navitoclax and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1315, NCI-2014-01043, 9608, NCT02143401
EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients with EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9903, NCI-2015-01270, NCT02520778
Start Over